Biology of Blood and Marrow Transplantation
Volume 12, Issue 4 , Pages 414-421 , April 2006

Graft-versus-Host Reactions and the Effectiveness of Donor Lymphocyte Infusions

Received 24 June 2005 ,Accepted 28 November 2005.

References 

  1. Weiden PL , Flournoy N , Thomas ED , et al.   Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts . N Engl J Med . 1979;300:1068–1073
  2. Weiden PL , Sullivan KM , Flournoy N , Storb R , Thomas ED . Antileukemic effect of chronic graft-versus-host disease . N Engl J Med . 1981;304:1529–1533
  3. Horowitz MM , Gale RP , Sondel PM , et al.   Graft-versus-leukemia reactions after bone marrow transplantation . Blood . 1990;75:555–562
  4. Kolb HJ , Mittermuller J , Clemm C , et al.   Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients . Blood . 1990;76:2462–2465
  5. Slavin S , Naparstek E , Nagler A , Ackerstein A , Kapelushnik J , Or R . Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes . Exp Hematol . 1995;23:1553–1562
  6. Collins RH , Shpilberg O , Drobyski WR , et al.   Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation . J Clin Oncol . 1997;15:433–444
  7. Dazzi F , Szydlo RM , Craddock C , et al.   Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia . Blood . 2000;95:67–71
  8. Mackinnon S , Papadopoulos EB , Carabasi MH , Reich L , Collins NH , O’Reilly RJ . Adoptive immunotherapy using donor leukocytes following bone marrow transplantation for chronic myeloid leukemia (is T cell dose important in determining biological response?) . Bone Marrow Transplant . 1995;15:591–594
  9. Collins RH , Rogers ZR , Bennett M , Kumar V , Nikein A , Fay JW . Hematologic relapse of chronic myelogenous leukemia following allogeneic bone marrow transplantation (apparent graft-versus-leukemia effect following abrupt discontinuation of immunosuppression) . Bone Marrow Transplant . 1992;10:391–395
  10. Mehta J , Powles R , Kulkarni S , Treleaven J , Singhal S . Induction of graft-versus-host disease as immunotherapy of leukemia relapsing after allogeneic transplantation (single-center experience of 32 adult patients) . Bone Marrow Transplant . 1997;20:129–135
  11. Elmaagacli AH , Beelen DW , Trenn G , Schmidt O , Nahler M , Schaefer UW . Induction of a graft-versus-leukemia reaction by cyclosporin A withdrawal as immunotherapy for leukemia relapsing after allogeneic bone marrow transplantation . Bone Marrow Transplant . 1999;23:771–777
  12. Kolb HJ , Schattenberg A , Goldman JM , et al.   Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia . Blood . 1995;86:2041–2050
  13. Porter DL , Collins RH , Hardy C , et al.   Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions . Blood . 2000;95:1214–1221
  14. Collins RH , Goldstein S , Giralt S , et al.   Donor leukocyte infusions in acute lymphocytic leukemia . Bone Marrow Transplant . 2000;26:511–516
  15. Kolb HJ . Donor leukocyte transfusions for treatment of leukemic relapse after bone marrow transplantation. EBMT Immunology and Chronic Leukemia Working Parties . Vox Sang . 1998;74(suppl 2):321–329
  16. Porter DL , Collins RH , Shpilberg O , et al.   Long-term follow-up of patients who achieved complete remission after donor leukocyte infusions . Biol Blood Marrow Transplant . 1999;5:253–261
  17. Luznik L , Fuchs EJ . Donor lymphocyte infusions to treat hematologic malignancies in relapse after allogeneic blood or marrow transplantation . Cancer Control . 2002;9:123–137
  18. Alyea E , Weller E , Schlossman R , et al.   T-cell-depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma (induction of graft-versus-myeloma effect) . Blood . 2001;98:934–939
  19. Salama M , Nevill T , Marcellus D , et al.   Donor leukocyte infusions for multiple myeloma . Bone Marrow Transplant . 2000;26:1179–1184
  20. Badros A , Barlogie B , Morris C , et al.   High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions . Blood . 2001;97:2574–2579
  21. Lokhorst HM , Schattenberg A , Cornelissen JJ , Thomas LL , Verdonck LF . Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation . Blood . 1997;90:4206–4211
  22. Porter DL , Roth MS , Lee SJ , McGarigle C , Ferrara JL , Antin JH . Adoptive immunotherapy with donor mononuclear cell infusions to treat relapse of acute leukemia or myelodysplasia after allogeneic bone marrow transplantation . Bone Marrow Transplant . 1996;18:975–980
  23. Thiede C , Bornhauser M , Oelschlagel U , et al.   Sequential monitoring of chimerism and detection of minimal residual disease after allogeneic blood stem cell transplantation (BSCT) using multiplex PCR amplification of short tandem repeat-markers . Leukemia . 2001;15:293–302
  24. Thiede C , Bornhauser M , Ehninger G . Strategies and clinical implications of chimerism diagnostics after allogeneic hematopoietic stem cell transplantation . Acta Haematol . 2004;112:16–23
  25. Van Deerlin VM , Leonard DG . Bone marrow engraftment analysis after allogeneic bone marrow transplantation . Clin Lab Med . 2000;20:197–225
  26. Sreenan JJ , Pettay JD , Tbakhi A , et al.   The use of amplified variable number of tandem repeats (VNTR) in the detection of chimerism following bone marrow transplantation. A comparison with restriction fragment length polymorphism (RFLP) by Southern blotting . Am J Clin Pathol . 1997;107:292–298
  27. Crescenzi B , Fizzotti M , Piattoni S , et al.   Interphase FISH for Y chromosome, VNTR polymorphisms, and RT-PCR for BCR-ABL in the monitoring of HLA-matched and mismatched transplants . Cancer Genet Cytogenet . 2000;120:25–29
  28. Przepiorka D , Weisdorf D , Martin P , et al.   1994 Consensus Conference on Acute GVHD Grading . Bone Marrow Transplant . 1995;15:825–828
  29. Atkinson K , Horowitz MM , Gale RP , Lee MB , Rimm AA , Bortin MM . Consensus among bone marrow transplanters for diagnosis, grading and treatment of chronic graft-versus-host disease. Committee of the International Bone Marrow Transplant Registry . Bone Marrow Transplant . 1989;4:247–254
  30. Jones RJ , Griffin CA , Smith BD , et al.   GM-CSF-mediated differentiation therapy following bone marrow transplantation (BMT) for chronic myeloid leukemia (CML) . [abstract] Blood . 1997;90:235a
  31. Bedi A , Griffin CA , Barber JP , et al.   Growth factor-mediated terminal differentiation of chronic myeloid leukemia . Cancer Res . 1994;54:5535–5538
  32. Petzer AL , Eaves CJ , Barnett MJ , Eaves AC . Selective expansion of primitive normal hematopoietic cells in cytokine-supplemented cultures of purified cells from patients with chronic myeloid leukemia . Blood . 1997;90:64–69
  33. Bhatia R , Munthe HA , Williams AD , Zhang F , Forman SJ , Slovak ML . Chronic myelogenous leukemia primitive hematopoietic progenitors demonstrate increased sensitivity to growth factor-induced proliferation and maturation . Exp Hematol . 2000;28:1401–1412
  34. Lokhorst HM , Wu K , Verdonck LF , et al.   The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma . Blood . 2004;103:4362–4364
  35. Dazzi F , Szydlo RM , Cross NC , et al.   Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia . Blood . 2000;96:2712–2716
  36. Luznik L , Slansky JE , Jalla S , et al.   Successful therapy of metastatic cancer using tumor vaccines in mixed allogeneic bone marrow chimeras . Blood . 2003;101:1645–1652
  37. Luznik L , Borrello I , Iannone R , et al.   In vivo priming of donor lymphocyte infusions by tumor vaccines after allogeneic bone marrow transplantation induces potent tumor immunity without lethal GVHD . Blood . 2000;96:581a
  38. Sehn LH , Alyea EP , Weller E , et al.   Comparative outcomes of T-cell-depleted and non-T-cell-depleted allogeneic bone marrow transplantation for chronic myelogenous leukemia (impact of donor lymphocyte infusion) . J Clin Oncol . 1999;17:561–568

PII: S1083-8791(05)00813-X

doi: 10.1016/j.bbmt.2005.11.520

Biology of Blood and Marrow Transplantation
Volume 12, Issue 4 , Pages 414-421 , April 2006

Article Tools

* Image Usage & Resolution